Rita Leporati
@rleporatimd.bsky.social
Medical Oncologist and Research Fellow @ UNIMORE, University Hospital of Modena, Italy 🇮🇹 circulating biomarkers & lung cancer
Reposted by Rita Leporati
💡It’s a pleasure to welcome the EORTC Early Career Investigators to our headquarters for the launch of the ECI course.
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
May 6, 2025 at 12:21 PM
💡It’s a pleasure to welcome the EORTC Early Career Investigators to our headquarters for the launch of the ECI course.
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
EORTC #YECIs have access to a global network of researchers and benefit from tailored educational programmes like this one.
👉https://www.eortc.org/early-career/
Histologic transformation of ALK-rearranged adenocarcinomas to high-grade LCNEC is a rare (4%) but significant resistance mechanism to ALK-TKIs, often co-occurring with on-target ALK mutations
👉🏻 doi.org/10.1016/j.cl...
👉🏻 doi.org/10.1016/j.cl...
Redirecting
doi.org
November 28, 2024 at 8:07 PM
Histologic transformation of ALK-rearranged adenocarcinomas to high-grade LCNEC is a rare (4%) but significant resistance mechanism to ALK-TKIs, often co-occurring with on-target ALK mutations
👉🏻 doi.org/10.1016/j.cl...
👉🏻 doi.org/10.1016/j.cl...